Safety and efficacy of recombinant acid alpha-glucosidase (rhGAA) in patients with classical infantile Pompe disease: results of a phase II clinical trial
- 1 January 2005
- journal article
- clinical trial
- Published by Elsevier in Neuromuscular Disorders
- Vol. 15 (1), 24-31
- https://doi.org/10.1016/j.nmd.2004.10.009
Abstract
No abstract availableKeywords
This publication has 13 references indexed in Scilit:
- Immune tolerance after long-term enzyme-replacement therapy among patients who have mucopolysaccharidosis IThe Lancet, 2003
- Identification of two subtypes of infantile acid maltase deficiencyThe Journal of Pediatrics, 2000
- Human Acid -Glucosidase from Rabbit Milk Has Therapeutic Effect in Mice with Glycogen Storage Disease Type IIHuman Molecular Genetics, 1999
- Frequency of glycogen storage disease type II in The Netherlands: implications for diagnosis and genetic counsellingEuropean Journal of Human Genetics, 1999
- Recombinant Human Acid -Glucosidase: High Level Production in Mouse Milk, Biochemical Characteristics, Correction of Enzyme Deficiency in GSDII KO MiceHuman Molecular Genetics, 1998
- High-level production of recombinant human lysosomal acid alpha-glucosidase in Chinese hamster ovary cells which targets to heart muscle and corrects glycogen accumulation in fibroblasts from patients with Pompe disease.Proceedings of the National Academy of Sciences, 1996
- Isolation and Characterisation of a Recombinant, Precursor form of Lysosomal Acid α‐GlucosidaseEuropean Journal of Biochemistry, 1995
- Left ventricular myocardial mass determined by cross-sectional echocardiography in normal newborns, infants, and childrenPediatric Cardiology, 1991
- Infantile acid maltase deficiencyVirchows Archiv B Cell Pathology Including Molecular Pathology, 1984
- The pathology of type II skeletal muscle glycogenosis. A light and electron-microscopic studyThe Journal of Pathology, 1975